科研速览 · Science Skim继续刷下去 · Keep skimming →
◆ Pituitary2026-08-07

Hypothalamic syndrome and acquired hypothalamic obesity: from fragmented care to integrated multidisciplinary management.

Betina Biagetti, Marta Ramon-Krauel, Juan José López Gómez, Irene Breton, Cristina Lamas, Assumpta Caixàs, Francisco PitaGutiérrez, María Dolores Ollero García, Albert Lecube, M Cristina Azcona-Sanjulian, Anna Aulinas, Esteban Cordero Asanza, Patricia Monsalve Martín, Marina Diaz Marsa, María D Ballesteros-Pomar

原始摘要(英文原文)· Original abstract
Acquired hypothalamic obesity (AHO) is a complex neuroendocrine disorder characterized by rapid weight gain and multisystem dysfunction following hypothalamic damage. AHO represents the weight-related manifestation of the broader hypothalamic syndrome (HS), a heterogeneous spectrum of dysfunctions that can also encompass disturbances in pituitary function, energy expenditure, sleep, behavior, and thermoregulation, with obesity itself absent in some affected individuals. This narrative review provides an updated and integrative overview of AHO pathophysiology, clinical characterization, and current and emerging approaches to diagnosis, prevention, and treatment, with the aim of proposing a multidimensional framework to improve patient care. The literature, including seminal studies, recent systematic reviews, clinical trials, and expert consensus statements, was critically appraised with emphasis on clinical applicability and existing knowledge gaps. Current evidence highlights the limitations of BMI-based assessment and supports a multidomain clinical approach. In this context, a three-layer diagnostic model is proposed, integrating etiological factors, longitudinal anthropometric and metabolic assessment, and domain-specific clinical evaluation. Preventive strategies remain underexplored, although hypothalamus-sparing interventions, early monitoring of weight trajectory, and management in specialized Pituitary Tumor Centers of Excellence in surgical cases appear critical. Therapeutic options are limited, with modest evidence for conventional treatments; however, emerging therapies targeting the melanocortin pathway, including MC4R agonists, showed promising results. Overall, AHO requires a paradigm shift toward early identification, multidimensional assessment, and coordinated multidisciplinary care, with future research prioritizing preventive strategies and robust clinical trials to improve outcomes.
读原文 · Read the paper ↗

AI 追问PRO

登录后使用 AI 追问

讨论区

登录后参与讨论

相关论文 · Related

Hypothalamic syndrome and acquired hypothalamic obesity: from fragmented care to integrated multidisciplinary management. — 科研速览 Science Skim